Hypogonadism Flashcards

1
Q

Terminology
hypogonadism
primary hypogonadism
secondary
* (Symptomatic) Late onset hypogonadism (S)LOH:
AOH
(P)ADAM
Testosterone deficiency (TD)

A
  • Hypogonadism: a condition resulting from or characterized by abnormally decreased
    functional activity of the gonads, with retardation of growth and sexual development.
  • Primary Hypogonadism: Primary disorder of testicular function
  • Secondary Hypogonadism: Disorders of the pituitary or hypothalamus resulting in
    inadequate gonadotropin stimulation of the testes.
  • (Symptomatic) Late onset hypogonadism (S)LOH: A clinical and biochemical syndrome
    associated with advancing age and characterized by typical symptoms and deficiency in
    serum testosterone levels. First used in guidelines in 2002.
  • AOH: Adult-onset hypogonadism
  • (P)ADAM: (Partial) androgen decline in the aging male
  • Andropause (International Society of the Study of the Ageing Male, ISSM): The term
    previously used to describe LOH.
  • Testosterone deficiency (TD) (ISSM, 2015): a clinical and biochemical syndrome
    characterized by a deficiency of testosterone, or testosterone action, and relevant
    symptoms and signs. TD may affect the function of multiple organ systems, and result in
    significant detriment in the quality of life, including alterations in sexual function.
  • Teststerone Deficiency Syndrome (TDS) (Canadian Guidelines 2015)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  • Which term is currently accepted as correct medical terminology?
    A. Andropause
    B. Low T
    C. Manopause
    D. Late onset hypogonadism (LOH)
    E. Partial androgen decline in the aging male (PADAM)
A

D. Late onset hypogonadism (LOH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does Testosterone Do?

A
  1. Fetal masculinization (i.e. become male)
  2. Pubertal changes (boy to man)
  3. Sexual function (have sex)
  4. Sperm production (reproduce)
  5. …. And so much more

◼ Decreased testicular production
◼ Testes less responsive
◼ Increase in sensitivity of the
hypothalamus
◼ Peripheral conversion to
estrogen
◼ SHBG increases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Classification * Primary
secondary

A

Primary * Testicular disorders * Testicular insults * Autoimmune syndrome * Secondary * GnRH deficiency * Hyperprolactinemia * Pituitary disorders * Medications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

OH is diagnosed by:
A. Patient reported questionnaire
B. Signs
C. Symptoms
D. Testosterone levels
E. Physical appearance, body habitus

A

B. Signs
C. Symptoms
D. Testosterone levels

Are they symptomatic? So that’s the first thing. You don’t just if someone has no symptoms, they have no complaints about I’m low libido or fatigue or anything like that, then you’re not going to bother working them up. You’re not just searching for a deficiency to treat. They have to have complaints that the deficiency is manifest in signs or symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Assessment – Signs and Symptoms

A

signs and symp of LOH
see slide 20`

more specific symp:
less specific symp
signs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Screening Tool - Example
* The ADAM Questionnaire

A

Do you have a decrease in libido?
* Do you have a lack of energy?
* Do you have a decrease in strength and/or endurance?
* Have you lost height?
* Have you noticed a decreased “enjoyment of life”?
* Are you sad and/or grumpy?
* Are your erections less strong?
* Have you noted a recent deterioration in your ability to play sports?
* Are you falling asleep after dinner?
* Has there been a recent deterioration in your work performance?
* If answered “yes” to question 1 or 7, or at least 3 of the other questions,
the patient may have low testosterone levels

We do not recommend using a screening tool because they have been mostly created by the pharmaceutical industry. So it doesn’t mean necessarily that that’s bad, that that’s evil, but it does mean that there is a bias. And so almost all of the tools that have been developed and used in clinical trials always seem to encourage people to take testosterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Screening - Questionnaires

A

Controversial
* Some developed by industry
* Biased toward supplementation
* Evidence – poor sensitivity and specificity
* CPG recommend not relying on these questionnaires

We do not recommend using a screening tool because they have been mostly created by the pharmaceutical industry. So it doesn’t mean necessarily that that’s bad, that that’s evil, but it does mean that there is a bias. And so almost all of the tools that have been developed and used in clinical trials always seem to encourage people to take testosterone

Are you grumpy? Is there less enjoyment in life? Again, like during COVID, we would have diagnosed pretty much every man with hypogonadism then because there was so much else going on. So they’re not very specific. They might tell you that there’s something that the patient needs more assessment for. But it shouldn’t be shouldn’t be used because the patient will end up thinking like, yeah, Now I need testosterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T Levels - Changes with Age
* Can be measured in:

A

◼ Between ages 25-75:
◼ T levels decrease 35%
◼ Free T decreases 50-60%
◼ At age 75
◼ 20% of men still have T levels in upper quartile of
values of young men
◼ FT and TT ↓ approx 1%/y starting in the third
decade (mean age 28)

  • Can be measured in:
  • saliva (not covered by Alberta Health)
  • urine (24-h collections)
  • blood work

*Ranges for bloodwork
* Total testosterone (TT) >12 nmol/L
* Borderline TT 8-12 nmol/L
* Low TT <8 nmol/L
* Free testosterone (FT) > 150 pmol/L
* approx 2% of TT

Oftentimes, there’s a calculation for free testosterone. It’s about 2% of total. These are the ranges that are generally given in most guidelines. So total testosterone should be greater than 12.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

T Levels
- Challenges with FT

A
  • Should be fasting morning level
  • Ideally between 7-11 AM
    there is a circadian rhythms, so the norms are established based on peaks in the morning. So that’s pretty big window 7-11. So make sure if you’re testing or assessing a patient, they have had their lab tests done correctly.
  • May be some variability by racial group
  • Some variability may be due to BMI and distribution of fat
  • Experts encouraging more research across populations for TT and FT
  • Refer to laboratory cut-points
  • Netcare = 10.3 – 29.5 nmol/L for AM TT
  • T measurement
  • fasting morning sample
  • May be repeated if the level is low
  • Borderline results may be clarified by the assessment of FT
  • Free T measurement challenges
  • The gold standard equilibrium dialysis methods are too complex for use in routine
    clinical laboratories, assays are not harmonized and consequently there are no
    common reference intervals to aid result interpretation.
  • FT - algorithms derived for calculation may not be accurate based on models related to
    SHBG variability
  • FT calculations have not been validated on some patient populations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Risk Factors - Medical
interfering factors w T level
see slide 28

A

see slide 30

pretty much every medical condition increases the risk for hypogonadism if it’s not managed.
And we could put COVID under inflammatory.
Obesity is TOP concern

Obesity is always problematic. For testosterone. It lowers total lowers free. Obesity is one of the greatest risks that we have.
f that patient has a vegetarian diet for a long period of time that can lower free testosterone, it’s thought that possibly fiber might, they maybe eat more fiber so that interferes with some absorption of steroids, re-absorption through the biliary tract

short intense exercise increases testosterone
t’s usually, it should be done in the morning, fasting, they get up, skipped breakfast, Go get your testosterone level done, eat your breakfast and then exercise later.

Smking increases T
someone may say they’re having symptoms and yet their testosterone level might be still within the normal range. But if they’re smoking, that can be problematic.

Alcohol abuse

Poorly managed chronic disease (any one cal lead to lower T)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Risk Factors – COVID

A
  • Mechanisms for ED
  • Endothelial dysfunction
  • Psychological distress
  • Impaired pulmonary hemodynamics
  • Exacerbation of CV disease
  • Impact on T levels
  • Sensory loss (anosmia, ageusia)
  • Italian study (n=100)
  • ED 28% vs 9.3% (p=0.027)

the inflammation throughout the body has just been established as just being just a storm of inflammation. And so the damage to the testes, it has now left some men severely hypogonadism. There’ll be on, it looks like chronic life-long testosterone supplementation

here are cases where young men, um, are now unable to have children there infertile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

COVID

A
  • Observations post-mortem
  • Testicular tissue has reduced Leydig cells, edema, inflammation
  • ACE-2 is expressed in testis and plays a role in spermatogenesis
    So this highlights that for testosterone, it’s so much more than just a sexual hormone. It’s also involved in other protection, other development of other organ systems. So pulmonary function, cardiovascular function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Medication Risk Factors
for Low T

A

Decreased T production Alcohol
Ketoconazole
LHRH agonists

T antagonists/Antiandrogens Spironolactone
Cimetidine
Flutamide
estrogens

Increased prolactin Phenothiazines
dopapmine blockers (metoclopramide, domperidone)
centrally-acting antihypertensive agents (methyldopa,
reserpine)

Increased SHBG Barbiturates
Anticonvulsants (e.g. carbamazepine)

Decreased DHT levels 5-alpha reductase inhibitors
saw palmetto

Others Antineoplastic drugs (e.g. cyclophosphamide,
chlorambucil)
(?) statins
Opioids (GnRH secretion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ClassificationClassification

A

see slide 36

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Goals for LOH

A
  • Restore normal physiologic effects of testosterone
  • Provide normal physiologic serum levels of hormones
  • Reverse target-organ changes
  • Improve QOL

It’s really to restore what could be a normal range of levels. And then also addressed some of those signs and symptoms. So the physiologic effects and improve quality of life.

17
Q

Treatment – Non-Pharmacologic

A
  • Before starting T therapy:
  • Address chronic conditions
  • Weight loss
  • Exercise
  • Osteoporosis
  • Sleep apnea
  • Discontinue medications that interfere with T

ome patients will be very motivated and make some behavioral changes, lifestyle changes, and that can normalize their testosterone.

This shows. A pretty linear relationship between body weight lost and total testosterone levels. So the more weight somebody loses if they’re obese already. This is, this was a study in obese patients. The higher their testosterone will be.

Sleep apnea: this is something that we want to encourage patients to seek care for. The more they’re hypoxic and the more their sleep is disrupted, we find them more impact this has on their testosterone levels.

18
Q

Treatment - Pharmacologic

A

“We recommend T therapy in hypogonadal men to induce and
maintain secondary sex characteristics and correct symptoms of T
deficiency

Testosterone - Evidence
* T-trials
* set of 7 multicentre, DB, PC studies
* evaluated the effects of T on:
* sexual function
* physical function
* vitality
* anemia
* bone mass
* cognition
* coronary artery plaque volume (cardiovascular substudy)
* T‐Trials not powered to assess the risks of prostate Ca or
CV events

19
Q

T- Evidence

A

Meta-analysis of the effect of testosterone on quality of life.

“Although study protocols and sample sizes vary considerably, there
are consistent findings of increased lean body mass, decreased fat,
and maintained or increased bone density in older men with low
serum testosterone levels but not in those with normal levels.”

Unfortunately, these are relatively small studies. We’re talking just hundreds of people, not thousands. And given the timeframe that it takes to monitor safety with prostate health. So cardiac, prostate cancer risk, and also cardiovascular events. You need a large sample and you need to follow them for a long enough period of time. So these studies have really have been disappointing in terms of looking at harm.

20
Q

Benefits of T Therapy

A

derm: increased hair gowth
cns: I’ll denote a small improvement in depressive moods. So in general, testosterone does seem to elevate mood. But if someone actually has depression, they’re diagnosed with depression. This is not something that’s going to reverse the depression.
cardio: we do know that if we can decrease fat mass, that probably should be a good thing. This is something that’s pretty consistent and it’s not like 30 kg or something. It’s usually a few kilograms. But even that can be motivating and encouraging for men.
geniturinary
msk
hematologic
endocrine

morning erections, erectile dysfunction in libido are usually addressed with testosterone therapy. So we should be monitoring those three specific symptoms.

some evidence using testosterone supplementation for months to years does decrease fracture risk

we increase red blood cell production with testosterone

bviously improvement in testosterone levels, obviously if we’re supplementing and then improvement in insulin sensitivity. So quite a few metabolic risks here are addressed.

21
Q

Contraindications to T Therapy

A

see slide 47

obstructive sleep apnea. if it’s untreated, such as we have more afib, we have more cognitive impairment with OSA.

severe hypertension, I mean, obviously like hypogonadism is this sort of gradual onset. It takes, takes a long time to develop. In most cases, if you’re dealing with something urgent, like someone’s just had a major cardiovascular event or their hypertension is not controlled. You’re going to deal with those more urgent things first before you’re going to introduce testosterone into the mix that could affect risks such as increased red blood cells and clotting risk

deal with BPH first, so we don’t want prostate growing and worsening BPH symptoms deal with fertility and then obviously any organ impairment.

generally if someone is being actively treated, you know, for most prostate cancers, this the chemotherapy involves medications that suppress testosterone sometimes to the point of castration levels. And so we’re not going to suddenly now introduce more testosterone that’s going to worsen that cancer growth.

22
Q

risk vs benefit

A

slide 48

Based on the evidence that we have. There’s a little bit of a range in terms of how this decision-making occurs. So the severity of the deficiency would weigh toward supplementing. And then on the right-hand side are situations where you would that the harm outweighs the benefit.

23
Q

T – Adverse Effects and Level of Evidence

A
  • Adverse events for which there is evidence of association with T
    administration
  • Erythrocytosis
  • Acne and oily skin
  • Detection of subclinical prostate cancer
  • Growth of metastatic prostate cancer
  • Reduced sperm production and fertility (read notes)
  • Uncommon AE for which there is weak evidence of association with T
    administration
  • Gynecomastia
  • Male pattern hair loss
  • Growth of breast cancer
  • Induction or worsening of OSA

T – Adverse Effects and Frequency

So when we increase testosterone, it obviously penetrates the CNS and does change things like mood, but sometimes it can cause a little bit too much aggression
Genital urinary, decreased sperm production, breast tenderness. S

24
Q

T – Adverse Effects
Formulation Specific

A

*IM injections
* Fluctuation in mood or libido
* Pain at injection site
* Coughing episodes immediately after injection

  • Transdermal patches
  • Frequent skin reactions at application site
  • Transdermal gels and solutions
  • Potential risk for T transfer to partner or another person who is in
    close contact
  • Skin irritation and odor at application site
  • Stickiness, slow drying, dripping
  • Buccal T tablets
  • Alterations in taste
  • Irritation of gums
  • Pellet implants
  • Infection, expulsion of pellet
  • T nasal gel
  • Rhinorrhea, epistaxis, nasal discomfort, nasal congestion,
    parosmia
  • Oral tablets
  • not recommended
  • Effects on liver and cholesterol
25
Q

Safety – CV (TOM Trial – T in Older Men)

A
  • To date no completed or
    published trials were
    powered or designed to
    adequately assess CV
    events.
  • Challenges: enrollment
    had heterogenous
    characteristics, studies
    were low/medium
    quality, different T doses
    and formulations,
    variable tx duration

Meta-analysis (Xu 2013)
* N=27 trials
* N=2994 men
* OR of CV event = 1.54 (1.09-2.18)
* OR if pharma funded = 0.89 (0.50-1.60)
* OR if non-funded = 1.06 (1.34-3.17)

  • Meta-analysis (Corona 2014)
  • N=75 trials
  • CV OR = 1.01 (0.57-1.77)
26
Q

Safety - CV
* Health Canada reccomendations

A

Health Canada (July 15, 2014)
* Health Canada has recently completed a safety review on testosterone replacement products. This review found a
growing body of evidence (from published scientific literature and case reports received by Health Canada and foreign
regulators) for serious and possible life-threatening heart and blood vessel problems such as heart attack, stroke, blood
clot in the lungs or legs; and increased or irregular heart rate with the use of testosterone replacement products. Health
Canada is working with manufacturers to update the Canadian product labels regarding this risk.

  • FDA
  • Statements (January 31, 2015; March 3, 2015)
  • FDA has concluded that there is a possible increased cardiovascular risk associated with testosterone use. These studies
    included aging men treated with testosterone. Some studies reported an increased risk of heart attack, stroke, or death
    associated with testosterone treatment, while others did not.
  • Additional label warnings regarding
  • The revised labels clarify the approved uses of these medications and include information about a possible increased risk of
    heart attacks and strokes in patients taking testosterone.
  • CMDh (November 2014, January 2015)
  • The Coordination Group for Mutual Recognition and Decentralised Procedures–Human - regulatory body representing
    European Union member states)
  • There is “no consistent evidence” of an increased risk for heart problems with testosterone products
27
Q

Safety - CV
* T-trials

A
  • Not powered to assess the risks of prostate Ca or CV events
  • TRAVERSE trial
  • first trial of T powered to assess CV events
  • N=6000+
  • began 2018
  • 5y exposure
  • Findings in approx 10 y
  • Application for practice
  • Individualize T treatment
  • risks and benefits